Early response of prostate carcinoma xenografts to docetaxel chemotherapy monitored with diffusion MRI

Dominique Jennings, B. Nicholas Hatton, Jingyu Guo, Jean-Philippe Galons, Theodore "Ted" Trouard, Natarajan Raghunand, James Marshall, Robert J. Gillies

Research output: Contribution to journalArticle

104 Citations (Scopus)

Abstract

For many anticancer therapies, it would be desirable to accurately monitor and quantify tumor response early in the treatment regimen. This would allow oncologists to continue effective therapies or discontinue ineffective therapies early in the course of treatment, and hence, reduce morbidity. This is especially true for second-line therapies, which have reduced response rates and increased toxicities. Previous works by others and ourselves have shown that water mobility, measured by diffusion-weighted magnetic resonance imaging (DW-MRI), increases early in tumors destined to respond to therapies. In the current communication, we further characterize the utility of DW-MRI to predict response of prostate cancer xenografts to docetaxel in SCID mice in a preclinical setting. The current data illustrate that tumor volumes and secreted prostate-specific antigen both respond strongly to docetaxel in a dose-responsive manner, and the apparent diffusion coefficient of water (ADCw) increases significantly by 2 days even at the lowest doses (10 mg/kg). The ADCw data were parsed by histogram analyses. Our results indicate that DW-MRI can be used for early detection of prostate carcinoma xenograft response to docetaxel chemotherapy.

Original languageEnglish (US)
Pages (from-to)255-262
Number of pages8
JournalNeoplasia
Volume4
Issue number3
DOIs
StatePublished - 2002

Fingerprint

docetaxel
Diffusion Magnetic Resonance Imaging
Heterografts
Prostate
Carcinoma
Drug Therapy
Therapeutics
Water
SCID Mice
Prostate-Specific Antigen
Tumor Burden
Neoplasms
Prostatic Neoplasms

Keywords

  • Apparent diffusion coefficient
  • Diffusion-weighted MRI
  • Docetaxel
  • Prostate carcinoma
  • Prostate-specific antigen

ASJC Scopus subject areas

  • Cancer Research

Cite this

Early response of prostate carcinoma xenografts to docetaxel chemotherapy monitored with diffusion MRI. / Jennings, Dominique; Nicholas Hatton, B.; Guo, Jingyu; Galons, Jean-Philippe; Trouard, Theodore "Ted"; Raghunand, Natarajan; Marshall, James; Gillies, Robert J.

In: Neoplasia, Vol. 4, No. 3, 2002, p. 255-262.

Research output: Contribution to journalArticle

Jennings, D, Nicholas Hatton, B, Guo, J, Galons, J-P, Trouard, TT, Raghunand, N, Marshall, J & Gillies, RJ 2002, 'Early response of prostate carcinoma xenografts to docetaxel chemotherapy monitored with diffusion MRI', Neoplasia, vol. 4, no. 3, pp. 255-262. https://doi.org/10.1038/sj/neo/7900225
Jennings, Dominique ; Nicholas Hatton, B. ; Guo, Jingyu ; Galons, Jean-Philippe ; Trouard, Theodore "Ted" ; Raghunand, Natarajan ; Marshall, James ; Gillies, Robert J. / Early response of prostate carcinoma xenografts to docetaxel chemotherapy monitored with diffusion MRI. In: Neoplasia. 2002 ; Vol. 4, No. 3. pp. 255-262.
@article{611deeb97050439eba758c9fe741b98c,
title = "Early response of prostate carcinoma xenografts to docetaxel chemotherapy monitored with diffusion MRI",
abstract = "For many anticancer therapies, it would be desirable to accurately monitor and quantify tumor response early in the treatment regimen. This would allow oncologists to continue effective therapies or discontinue ineffective therapies early in the course of treatment, and hence, reduce morbidity. This is especially true for second-line therapies, which have reduced response rates and increased toxicities. Previous works by others and ourselves have shown that water mobility, measured by diffusion-weighted magnetic resonance imaging (DW-MRI), increases early in tumors destined to respond to therapies. In the current communication, we further characterize the utility of DW-MRI to predict response of prostate cancer xenografts to docetaxel in SCID mice in a preclinical setting. The current data illustrate that tumor volumes and secreted prostate-specific antigen both respond strongly to docetaxel in a dose-responsive manner, and the apparent diffusion coefficient of water (ADCw) increases significantly by 2 days even at the lowest doses (10 mg/kg). The ADCw data were parsed by histogram analyses. Our results indicate that DW-MRI can be used for early detection of prostate carcinoma xenograft response to docetaxel chemotherapy.",
keywords = "Apparent diffusion coefficient, Diffusion-weighted MRI, Docetaxel, Prostate carcinoma, Prostate-specific antigen",
author = "Dominique Jennings and {Nicholas Hatton}, B. and Jingyu Guo and Jean-Philippe Galons and Trouard, {Theodore {"}Ted{"}} and Natarajan Raghunand and James Marshall and Gillies, {Robert J.}",
year = "2002",
doi = "10.1038/sj/neo/7900225",
language = "English (US)",
volume = "4",
pages = "255--262",
journal = "Neoplasia",
issn = "1522-8002",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Early response of prostate carcinoma xenografts to docetaxel chemotherapy monitored with diffusion MRI

AU - Jennings, Dominique

AU - Nicholas Hatton, B.

AU - Guo, Jingyu

AU - Galons, Jean-Philippe

AU - Trouard, Theodore "Ted"

AU - Raghunand, Natarajan

AU - Marshall, James

AU - Gillies, Robert J.

PY - 2002

Y1 - 2002

N2 - For many anticancer therapies, it would be desirable to accurately monitor and quantify tumor response early in the treatment regimen. This would allow oncologists to continue effective therapies or discontinue ineffective therapies early in the course of treatment, and hence, reduce morbidity. This is especially true for second-line therapies, which have reduced response rates and increased toxicities. Previous works by others and ourselves have shown that water mobility, measured by diffusion-weighted magnetic resonance imaging (DW-MRI), increases early in tumors destined to respond to therapies. In the current communication, we further characterize the utility of DW-MRI to predict response of prostate cancer xenografts to docetaxel in SCID mice in a preclinical setting. The current data illustrate that tumor volumes and secreted prostate-specific antigen both respond strongly to docetaxel in a dose-responsive manner, and the apparent diffusion coefficient of water (ADCw) increases significantly by 2 days even at the lowest doses (10 mg/kg). The ADCw data were parsed by histogram analyses. Our results indicate that DW-MRI can be used for early detection of prostate carcinoma xenograft response to docetaxel chemotherapy.

AB - For many anticancer therapies, it would be desirable to accurately monitor and quantify tumor response early in the treatment regimen. This would allow oncologists to continue effective therapies or discontinue ineffective therapies early in the course of treatment, and hence, reduce morbidity. This is especially true for second-line therapies, which have reduced response rates and increased toxicities. Previous works by others and ourselves have shown that water mobility, measured by diffusion-weighted magnetic resonance imaging (DW-MRI), increases early in tumors destined to respond to therapies. In the current communication, we further characterize the utility of DW-MRI to predict response of prostate cancer xenografts to docetaxel in SCID mice in a preclinical setting. The current data illustrate that tumor volumes and secreted prostate-specific antigen both respond strongly to docetaxel in a dose-responsive manner, and the apparent diffusion coefficient of water (ADCw) increases significantly by 2 days even at the lowest doses (10 mg/kg). The ADCw data were parsed by histogram analyses. Our results indicate that DW-MRI can be used for early detection of prostate carcinoma xenograft response to docetaxel chemotherapy.

KW - Apparent diffusion coefficient

KW - Diffusion-weighted MRI

KW - Docetaxel

KW - Prostate carcinoma

KW - Prostate-specific antigen

UR - http://www.scopus.com/inward/record.url?scp=0036097294&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036097294&partnerID=8YFLogxK

U2 - 10.1038/sj/neo/7900225

DO - 10.1038/sj/neo/7900225

M3 - Article

VL - 4

SP - 255

EP - 262

JO - Neoplasia

JF - Neoplasia

SN - 1522-8002

IS - 3

ER -